Your cutting-edge expert with the resources to manage your pharmacy program effectively, contain cost, and be accountable for the results. We are the next generation; we are the solution.
The Rebate Bubble by Jonalan Smith, PharmD, FASCP, Senior Vice President Everyone knows the recent ‘bubbles’ that have impacted the economy in major way: The
The Impact Of Humira Citrate-Free by Bob Kordella, R.Ph., MBA Humira is typically in the top five drugs by spend for most plan sponsors. In
HIV PrEP Therapies by Darian Hurst, Vice President In June 2019, the United States Preventive Services Task Force (USPSTF) published a final recommendation that clinicians
Pharmacy renegotiation through Excelsior Solutions Annual Pharmacy Savings of $6.3M (23%
Using Data to Identify Fraudulent Claims Pharmacy Reimbursement of $26,000 Challenge
Opioid Case Study Annual Savings of $192,000 Challenge Member filling pain
With increasing specialty drug costs, pharmacy benefit managers,health plans and industry experts often tout the use of biosimilarsas a strategy to lower cost. In 2013,
As you may recall, back in March of this year, Eli Lilly announced that they would begin to manufacture and sell an authorized generic version
The news that the FDA approved the first A-rated (meaning that pharmacists may freely substitute it without physician approval) generic form of Advair Diskus on
Hello, everyone, and welcome to this week’s edition of Excelsior Solutions’ ICER Update.Here is this week’s ICER recap: ICER released a Draft Evidence Report for
NOTE: Since today’s update was written, ICER has announced either the indefinite postponement (Sickle Cell Disease, Cystic Fibrosis) or 2 to 3 month delay (NASH,
Hello, everyone, and welcome to this week’s edition of Excelsior Solutions’ ICER Update. Here is this week’s ICER recap: ICER released a draft evidence report
© Copyright 2019 Excelsior Solutions • Privacy Policy • All Rights Reserved